$21.5m · Other round · Healthtech · Akureyri, Iceland
Image: Arctic Therapeutics, via the official funding announcement.
Arctic Therapeutics, an Icelandic clinical-stage biopharmaceutical company developing treatments from human-genetics research, has closed $21.5m in an oversubscribed financing round, led by Pekron, Sanos Group, Kaldbakur and Landvættir. The company said the capital will move AT-002 and AT-003 towards clinical development, broadening its pipeline beyond two programmes that have already reached Phase II milestones.
A portfolio reset after clinical milestones
Arctic Therapeutics builds drug programmes around genetic variants that point to disease mechanisms. AT-002 is a peptide mimetic designed to inhibit the JAK-STAT signalling pathway and is initially being developed for autoimmune uveitis. AT-003 is a small-molecule programme targeting mitochondrial quality control and autophagy linked to CLEC16A, a gene associated with several autoimmune diseases. Both remain on the path towards clinical development; the financing does not mean either has entered human trials.
The round therefore marks a sequencing decision across the portfolio. Arctic Therapeutics says its approximately $31m Series A financed progress for AT-001, an oral treatment being studied in hereditary amyloid angiopathy and Alzheimer's disease, and AT-004, a topical anti-inflammatory programme that has completed a Phase IIa acne study. With those lead assets at clinical milestones, the company plans to use the new capital on earlier programmes while pursuing partnering and out-licensing for AT-001 and AT-004.
That model can spread scientific risk without requiring one balance sheet to fund every programme through late-stage trials. But it also creates two linked execution tests: Arctic Therapeutics must generate the preclinical and regulatory evidence needed to bring AT-002 and AT-003 into the clinic, while finding partners able to finance and operate the next stages of its more advanced assets. The value of the round will depend less on pipeline breadth alone than on whether each programme reaches a hand-off point that specialist partners will fund.
Extending the clinical-development network
The financing follows Arctic Therapeutics' participation in the acquisition of Nobias Therapeutics' lead asset and the July 2026 launch of Synaptiq Therapeutics. That programme, now called SYN-001, is being prepared for a Phase IIb study in 22q11.2 deletion syndrome after receiving FDA Rare Pediatric Disease and Orphan Drug designations. Arctic Therapeutics provides Synaptiq with clinical-development infrastructure and scientific and operational support.
This gives the company another route to apply its development capabilities without owning every asset outright. It also raises the operational bar: several programmes, partners and disease areas have to move on different regulatory timelines. The oversubscribed round gives Arctic Therapeutics additional capital and investor backing for that portfolio strategy, but the next meaningful evidence will be programme-specific: clinical-entry packages for AT-002 and AT-003, partnership progress for AT-001 and AT-004, and execution of Synaptiq's planned trial.
